MUMBAI, Feb 22: Pharma major, Granules India on Saturday said that its board has approved to acquire 100% stake in Senn Chemicals AG, a Swizterland based company, for a total consideration of Rs 192.5 crore.
Krishna Prasad Chigurupati, chairman & managing director, Granules India, said, “The acquisition
of Senn Chemicals AG marks a significant milestone in Granules’ strategic growth journey. By entering the rapidly growing peptide therapeutics segment and acquiring CDMO capabilities, we
are expanding into next-generation therapeutics that align with our commitment to innovation and affordability.”
Senn Chemicals AG, a Swiss-based CDMO specializing in peptides. It develops and manufactures, Peptides and peptides based applications for its global customers, providing contract research, development, and manufacturing services.
The acquisition brings Senns expertise in liquid-phase peptide synthesis (LPPS) and solid-phase peptide synthesis (SPPS), along with a strong CDMO business and established customer relationship, including innovators and brand owners across Pharma, Cosmetics, Amino Acid Derivatives (AAD) & theragnostic segments.
The acquisition aligns with Granules vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market, including GLP-1 receptor agonists and other next-generation therapeutics. Granules and Senn have been developing two GLP-1 based APIs, and both the projects are progressing well, and more peptide-based APIs are planned to be added in the portfolio, to be developed using Senns R&D capabilities.
The transaction is expected to be completed in the first half of calendar year 2025, he added. (UNI)
The post Granules India acquires 100 pc stake in Senn Chemicals AG appeared first on Daily Excelsior.